AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34965712
Drug: Rehabilitation complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation complex including therapeutic exercises, mechanotherapy, electrical stimulation, gravitational therapy, and antiresorptive therapy (10 procedures)
Trial: 39256427
Drug: Drug-eluting stent
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stent (DES)
Trial: 32511143
Drug: Multimodal group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal group received infiltration with 0.5% bupivacaine 92.5 mg (18.5 mL), ketorolac 30 mg (1 mL), morphine 5 mg (0.5 mL), and epinephrine 0.5 mg (0.5 mL)
Trial: 34351426
Drug: β‐blocker therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β‐blocker therapy (agent and dose according to treating physician)
Trial: 33829225
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of subsidies on healthy products and taxes on unhealthy products in the nudging and price salience condition
Trial: 36708956
Drug: Agomelatine 25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine 25-50 mg/day
Trial: 34996516
Drug: Antimicrobial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial therapy
Trial: 36495775
Drug: Protective ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protective ventilation (PV): tidal volume = 6 ml/kg of predicted body weight, PEEP = 10 cmH2O, recruitment maneuvers
Trial: 33553968
Drug: Follow-up after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up after therapy
Trial: 34958394
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of carbide burs and Sof-Lex discs
Trial: 36659832
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (not explicitly mentioned in the abstract)
Trial: 33938307
Drug: PGX-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGX-guided treatment
Trial: 32941700
Drug: Angiotensin receptor
RxNorm normalized name: Angiotensin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor blocker
Trial: 32208439
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blocker
Trial: 35576956
Drug: Adebrelimab plus
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab plus chemotherapy (carboplatin and etoposide)
Trial: 35576956
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus chemotherapy (carboplatin and etoposide)
Trial: 39671272
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus chemotherapy
Trial: 33472641
Drug: Hypertonic sodium
RxNorm normalized name: Sodium Chloride Topical application Dressing [CURITY HYPERTONIC SODIUM CHLORIDE PACKING STRIP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic sodium infusion
Trial: 33010371
Drug: i-gel supraglottic
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i-gel supraglottic airway device (SGA)
Trial: 35731889
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of suvorexant
Trial: 32207140
Drug: Medical expulsive
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical expulsive therapy (MET) with 0.4 mg daily tamsulosin
Trial: 32196621
Drug: Myo-inositol (MI)
RxNorm normalized name: myo-inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myo-inositol (MI) treatment
Trial: 33753043
Drug: dd‐MVAC (dose‐dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dd‐MVAC (dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin)
Trial: 36054143
Drug: Moxifloxacin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (800 mg/day for 4 days)
Trial: 35578103
Drug: Participatory art-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participatory art-based activity (2 hours weekly for 12 weeks)
Trial: 34753480
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg orally once daily
Trial: 34258380
Drug: Dual antithrombotic
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antithrombotic therapy (DAT) with apixaban plus clopidogrel
Trial: 34258380
Drug: Triple antithrombotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antithrombotic therapy (TAT) with vitamin-K-antagonist (VKA) plus clopidogrel and acetylsalicylic acid
Trial: 32670199
Drug: Jinlida granules,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinlida granules, 9 g/time, three times daily for 2-4 years, in addition to lifestyle intervention
Trial: 32670199
Drug: Placebo, orally,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, orally, 9 g/time, three times daily for 2-4 years, in addition to lifestyle intervention
Trial: 34905220
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of primaquine (0.0625 to 0.5 mg base/kg)
Trial: 35504639
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care consisting of analgesia, and regular input from the medical and therapy team.
Trial: 33871648
Drug: Capsaicin 179
RxNorm normalized name: Capsaicin 179 mg cutaneous patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin 179 mg cutaneous patch
Trial: 39339810
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment
Trial: 38537483
Drug: Cognitive Remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Remediation Therapy (CRT)
Trial: 32115517
Drug: Control therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy
Trial: 32817142
Drug: 99mTc-ADAPT6 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc-ADAPT6 (500 μg)
Trial: 32817142
Drug: 99mTc-ADAPT6 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc-ADAPT6 (250 μg)
Trial: 32817142
Drug: 99mTc-ADAPT6 (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc-ADAPT6 (1,000 μg)
Trial: 36217555
Drug: Cold Atmospheric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold Atmospheric Plasma (CAP) treatment biweekly for five sessions
Trial: 33495378
Drug: Genetic predisposition
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetic predisposition to insulin resistance
Trial: 34044738
Drug: Breathing exercise
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breathing exercise program performed twice per day for one month
Trial: 35078923
Drug: Induction chemoimmunotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemoimmunotherapy followed by chemotherapy-free radioimmunotherapy (RIT)
Trial: 32776464
Drug: L-citrulline (CIT)
DrugBank: Citrulline (DB00155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-citrulline (CIT) supplementation (6g/day)
Trial: 34074559
Drug: Dual immunotherapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual immunotherapy of ipilimumab and nivolumab
Trial: 35578303
Drug: Prolonged requirement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged requirement for insulin (PRI) on Day 5
Trial: 35578303
Drug: No prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prolonged requirement for insulin (non-PRI)
Trial: 32679238
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment plus usual care
Trial: 33433786
Drug: Primary IORT
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary IORT with compliance to endocrine therapy
Trial: 35369700
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of standard therapy (control group)
Trial: 35102424
Drug: THC (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (both doses)
Trial: 39160110
Drug: Conventional oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oxygen therapy
Trial: 34910143
Drug: DMPA-IM vs
RxNorm normalized name: DMPA
DrugBank: Zytron (DB11768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMPA-IM vs LNG implant
Trial: 33336360
Drug: Titrated oral
RxNorm normalized name: magnesium citrate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated oral misoprostol solution (OMS)
Trial: 32935261
Drug: Parent-Child Interaction
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-Child Interaction Therapy focused on Emotional Development (PCIT-ED), n = 114
Trial: 34308314
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 2400 mg/day for 12 weeks
Trial: 35272971
Drug: Closed-loop insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop insulin delivery (Cambridge hybrid closed-loop algorithm)
Trial: 35272971
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care with insulin pump therapy (control group)
Trial: 35272971
Drug: Closed-loop insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop insulin delivery (FlorenceM configuration)
Trial: 35272971
Drug: Closed-loop insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop insulin delivery (CamAPS FX configuration)
Trial: 33082016
Drug: LSD 5
RxNorm normalized name: Lysergic acid diethylamide
DrugBank: Lysergic acid diethylamide (DB04829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSD 5 mcg
Trial: 33082016
Drug: LSD 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSD 10 mcg
Trial: 32856251
Drug: Zinc threonine
RxNorm normalized name: Threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc threonine chelate (80 and 120 mg zinc per kg feed)
Trial: 32856251
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (no zinc supplementation)
Trial: 32856251
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate (40, 80, and 120 mg zinc per kg feed)
Trial: 32856251
Drug: Commercial chelate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial chelate (Bioplex Zn®) (40 mg zinc per kg feed)
Trial: 33930380
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg orally followed by misoprostol 800 mcg vaginally 24 hours later
Trial: 33513929
Drug: 548 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 548 mg/day of polyphenols and 2 g/day of L-citrulline for 6 weeks
Trial: 32663102
Drug: Indacaterol 110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol 110 µg/glycopyrronium 50 µg once daily (OD)
Trial: 32663102
Drug: Tiotropium 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 50 µg OD
Trial: 35595661
Drug: TAK-214 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-214 vaccine (15/15, 15/50, 50/50, or 50/150 μg of GI.1/GII.4c genotype VLPs with 0.5 mg Al(OH)3)
Trial: 39449089
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment control
Trial: 33476659
Drug: Mifepristone followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone followed by misoprostol (200 mg oral mifepristone followed by 800 mcg vaginal misoprostol)
Trial: 37428480
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg)
Trial: 33687525
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug (JAK inhibitor)
Trial: 35725922
Drug: Licogliflozin 150
RxNorm normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licogliflozin 150 mg
Trial: 35725922
Drug: Licogliflozin 30
RxNorm normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licogliflozin 30 mg
Trial: 33951362
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg intravenous)
Trial: 33593789
Drug: Multifaceted intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifaceted intervention including nutrition optimization, parenting program with cognitive-behavioral therapy, lifestyle behavior change, and reduction of environmental pollution.
Trial: 32065939
Drug: COPE (integrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPE (integrated treatment using prolonged exposure)
Trial: 32065939
Drug: Seeking Safety
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seeking Safety (integrated therapy using cognitive behavioral, interpersonal techniques and case management)
Trial: 36477031
Drug: Ipilimumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (3 mg/kg)
Trial: 35074903
Drug: Ipilimumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (3 mg/kg) + Nivolumab (1 mg/kg)
Trial: 36262221
Drug: Adapted person-centered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted person-centered prescription (PCP) model
Trial: 35221687
Drug: Vortioxetine 10
RxNorm normalized name: vortioxetine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine 10 mg
Trial: 35221687
Drug: Vortioxetine 20
RxNorm normalized name: vortioxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine 20 mg
Trial: 33879733
Drug: rhBNP group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhBNP group (basic treatment combined with rhBNP)
Trial: 33879733
Drug: standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard treatment group (treated with an angiotensin‐converting enzyme inhibitor, β receptor blocker, and corticosteroid antagonist)
Trial: 37815957
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment
Trial: 37660042
Drug: High-Intensity Laser
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Laser Therapy (HILT)
Trial: 35099263
Drug: Mentalization-Based Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization-Based Therapy Intensive Outpatient (MBT-IOP)
Trial: 35099263
Drug: Mentalization-Based Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization-Based Therapy Day Hospital (MBT-DH)
Trial: 34430672
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma therapy (CPT)
Trial: 32259774
Drug: Alpha lipoic
RxNorm normalized name: Alpha Lipoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha lipoic acid (ALA) 300 mg twice daily for 3 months
Trial: 36416836
Drug: Ipilimumab or
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab or high-dose interferon α 2b (HDI)
Trial: 33650299
Drug: Selenious yeast
RxNorm normalized name: Selenious Acid
DrugBank: Selenious acid (DB11127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenious yeast tablet (SYT) for 6 months
Trial: 34562067
Drug: Placebo (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (single ascending dose)
Trial: 35042007
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow aspirate concentrate (BMAC) augmentation
Trial: 33793636
Drug: High volume
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High volume simethicone (1125 mg in 750 ml water)
Trial: 33793636
Drug: Standard volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard volume simethicone (300 mg in 200 ml water)
Trial: 32992151
Drug: Enhanced Treatment-As-Usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Treatment-As-Usual (ETAU)
Trial: 32479135
Drug: DRM02, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRM02, a novel phosphodiesterase-4 inhibitor, applied topically in mouse models.
Trial: 32479135
Drug: DRM02, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRM02, a novel phosphodiesterase-4 inhibitor, applied topically in a mouse model of psoriasis.
Trial: 32479135
Drug: DRM02 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DRM02 treatment of cultured primary human and mouse epidermal keratinocytes.
Trial: 35189669
Drug: Repeat colonoscopy
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat colonoscopy with adequate bowel preparation
Trial: 38795110
Drug: Warfarin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin therapy
Trial: 33305626
Drug: 50000 IU
RxNorm normalized name: Ergocalciferol 50000 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50000 IU vitamin D weekly for 12–14 weeks
Trial: 32843286
Drug: Vestronidase alfa,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestronidase alfa, rhGUS enzyme replacement therapy
Trial: 32648260
Drug: CNS relapse
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CNS relapse treatment (heterogeneous)
Trial: 34864649
Drug: Timolol nasal
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol nasal spray (1 mg/d)
Trial: 35968287
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy (NRT)
Trial: 36454906
Drug: Blueberry (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blueberry (250 g)
Trial: 38762798
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen
Trial: 33787042
Drug: Pectin-containing enteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pectin-containing enteral formula (Hine E-Gel®)
Trial: 35870947
Drug: Taurine supplementation
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taurine supplementation (1 g Taurine, n = 60)
Trial: 38628260
Drug: Pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy
Trial: 33033101
Drug: Vedolizumab 300
RxNorm normalized name: vedolizumab 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab 300 mg
Trial: 36399081
Drug: Negative control
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative control (no implants)
Trial: 39758967
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: 33652093
Drug: Hospice representatives
RxNorm normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hospice representatives reporting missing opioid medications
Trial: 33652093
Drug: Hospice representatives
RxNorm normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hospice representatives reporting disposal practices of medications after home deaths
Trial: 33187916
Drug: Concurrent apatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent apatinib and brain radiotherapy (BR)
Trial: 33199417
Drug: Semaglutide 0.5
RxNorm normalized name: semaglutide 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide 0.5 mg
Trial: 36801984
Drug: Semaglutide 1.0
RxNorm normalized name: SEMAGLUTIDE 1.0 mg in 0.5 mL SUBCUTANEOUS INJECTION, SOLUTION [WEGOVY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide 1.0 mg
Trial: 34255168
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics in combination with cognitive remediation therapy (AP + CR)
Trial: 34255168
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (AP)
Trial: 35050837
Drug: RVT-1601 10
RxNorm normalized name: RVT-801
DrugBank: ACG-801 (DB17659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RVT-1601 10 mg
Trial: 35050837
Drug: RVT-1601 40
RxNorm normalized name: RVT-801
DrugBank: ACG-801 (DB17659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RVT-1601 40 mg
Trial: 35050837
Drug: RVT-1601 80
RxNorm normalized name: RVT-801
DrugBank: ACG-801 (DB17659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RVT-1601 80 mg